Authors concluded that TREM2 down-regulation may improve the results of anti-PD-L1 therapy in HCC by increasing the anti-tumor CD8+T cells’ action, and indicated that targeted anti-TREM2 immunotherapy may improve therapeutic outcomes after TACE, which itself remains a promising HCC treatment strategy [87]. This evidence concerns the gene CD274 and hepatocellular carcinoma.